Sildenafil in COVID-19

• Status: Completed
• Trial end date: 2021-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This randomised trial aims to assess the role of sildenafil in improving oxygenation amongst hospitalised patients with COVID19.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidad Nacional Andres Bello
• Collaborator: Hospital Naval Almirante Nef, Viña del Mar, Chile
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

• Adult participant with high clinical suspicion of a SARS-CoV2 infection.

• Hypoperfusion of healthy lung areas in a substraction computed tomography angiography within 24 hours of admission to the hospital.

Exclusion Criteria:

• Requirement of therapy with nitrates of nitrites

• Arterial hypotension at presentation

• Recent diagnosis of coronary artery disease (<6 months)

• Acute heart failure at presentation

• Recent stroke (< 6 months)

• Chronic respiratory failure with CO2 retention

• Known hypersensitivity to sildenafil

• Advanced liver disease (Child-Pugh class B or higher)

• Users of cytochrome P450 3A4 inhibitors (Erythromycin, Ketoconazole, Itraconazole, Saquinavir)

• Pulmonary hypertension

• Chronic users of phosphodiesterase 5 inhibitors

• Requirement of invasive mechanical ventilation at baseline

• Decision to limit therapeutic efforts at baseline

• Pregnancy or lactation

• History of retinitis pigmentosa

• Known obstruction to left-ventricular outflow tract

• Unwillingness to participate in the trial